<DOC>
	<DOCNO>NCT02465801</DOCNO>
	<brief_summary>The purpose study evaluate dosage recombinant human serum albumin/granulocyte colony-stimulating factor fusion protein injection prevent neutrophilic granulocytopenia among chemotherapy patient . Conduct Pharmacokinetics ( PK ) study recombinant human serum albumin/granulocyte colony-stimulating factor fusion protein recombinant human granulocyte colony-stimulating factor injection control .</brief_summary>
	<brief_title>Study Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein</brief_title>
	<detailed_description>- Brief Protocol : Treat patient take Taxotere+Epirubicin+Cyclophosphamide ( TEC ) treatment Taxotere+Epirubicin ( TE ) treatment chemotherapy study medicine positive control period two chemotherapy treatment . - Positive control：recombinant human granulocyte colony-stimulating factor injection . - Targeted patient : breast cancer - Grouping : Group 1 : 1.2 mg recombinant human serum albumin/granulocyte colony-stimulating factor fusion protein TEC TE treatment ; Group 2 : 1.5 mg recombinant human serum albumin/granulocyte colony-stimulating factor fusion protein TEC TE treatment ; Group 3 : positive control TEC TE treatment . - Number patient : 216 - Concomitant medicine conduct .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Age 1865 . Diagnosed breast cancer , suitable TEC TE . ECOG performance status 0 1 . Adjuvant chemotherapy ; new adjuvant chemotherapy ; newly diagnose class Ⅳ prior chemotherapy . ANC≥1.5×10 9/L , PLT≥100×10 9/L . No bone marrow metastasis , blood coagulation function normally , Hemorrhagic tendency . No obvious abnormal ecg examination . TBIL , ALT , AST≤2.5×ULN ( ≤5×ULN presence hepatic metastasis ) . Cr , BUN≤2.5×ULN . Signed informed consent . Chemotherapy within past 4 week Uncontrolled inflammatory disease , axillary temperature≥38℃ . Merging malignant tumor Pregnancy nursing status . Participation another clinical trial investigational product within 3 month prior study entry . Severe diabetes mellitus , poor blood sugar controller . Allergic disease allergic constitution . History protein allergy . History drug addiction alcoholism . Hematopoietic stem cell transplantation organ transplantation . Chronic disease severe cardiac , kidney liver . Other condition would exclude study accord doctors'judgment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>